slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
WBA PowerPoint Presentation
Download Presentation
WBA

Loading in 2 Seconds...

play fullscreen
1 / 24

WBA - PowerPoint PPT Presentation


  • 117 Views
  • Uploaded on

WBA. Zin en onzin PSA bepaling en prostaatbehandeling L. Denis Oncologisch Centrum Antwerpen 25 april 2005. PSA: a serine protease enzyme secreted by epithelial cells of the prostate. In the serum as a free uncomplexed form ACT alpha-1-antichymotrypsin

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'WBA' - soyala


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
WBA

Zin en onzin PSA bepaling en prostaatbehandeling

L. Denis

Oncologisch Centrum Antwerpen

25 april 2005

psa a serine protease enzyme secreted by epithelial cells of the prostate
PSA: a serine protease enzymesecreted by epithelial cells of the prostate

In the serum as a free uncomplexed form

ACT alpha-1-antichymotrypsin

alpha 2M alpha-2-macroglobulin

other acute phase proteins

Identified in 1982 as follow-up marker.

in 1987 as diagnostic marker.

in essence tissue marker

Nakamura, 2002

psa validation of a tumour marker
PSA validation of a tumour marker

A marker produced by cancer cells, detectable in body fluids, easily measurable.

A PCa marker, PSA is tissue specific becomes a tumour marker after diagnosis.

Long evolution of disease in elderly patients (co-morbidity) make prognostic value (surrogate marker of survival) difficult.

L. Boccon-Gibod, 2005

psa assay development
PSA assay development

Total PSA equimolar response for free and PSA ACT complexes.

Free PSA in serum separated in 3 hours and assayed in 24 hours.

Reference values to be established for each assay combination.

ICUD, 2002

results internal surveys erspc 2004
Results internal surveys ERSPC 2004

Remarks:

1. April results Helsinki not taken into account (extreme outliers)

psa in clinical practice
PSA in clinical practice.

Prior to any treatment (repeat once).

After treatment with curative intent.

After treatment hormones/medication.

OCA, 2005

psa a non ideal test for pca screening
PSA: A Non-Ideal Test for PCa Screening
  • Lack of sensitivity

With a cut-off point of 4 ng/ml, 20-30% of cancers will be missed

  • Lack of specificity

Only 1 in 4 men with a PSA level of 4-10 ng/ml will have PCa following needle biopsy

psa validation as a pca tumour marker
PSA validation as a PCa tumour marker

The optimal upper limit of normal for PSA for PCa screening is unknown. New biomarkers are needed linked to prognosis and prognostic validated trials.

I. Thompson, 2004

slide12

BPSA

(degraded PSA)

BPH

Transition Zone

Central

Zone

Prostate

Peripheral Zone

cancer

pPSA

(precursor PSA)

enhancing psa as a screening test
Enhancing PSA As A Screening Test
  • PSA density
  • Age-related reference ranges
  • Serial assays (PSA velocity – doubling time)
  • PSA isoform assays
    • Free PSA
    • Complexed PSA
    • Precursor PSA
    • Pro-PSA
    • B-form PSA
    • Mature form PSA
psa gimmicks
PSA gimmicks

DUST study shows that PSA, PSA D, TZ.PSA D and% free PSA do not enhance specificity for PCa detection in PSA 3-15 ng/ml.

Michielsen D. et al, 2005

psa diagnosis based on free to total
PSA diagnosis based on % free to total

The final pathology or predictive value by t PSA or symptomatic biopsy is not improved by % f/t PSA.

Miyake H., 2005

a note of concern f t psa for pca detection
A note of concern: f/t PSA for PCa detection.

Using invalidated combinations of f and t assays may increase the number of unnecessary biopsies. Cut points need to be validated for each individual assay.

Oberpenning F. et al, 2002

psa indicator of clinical significance
PSA indicator of clinical significance

Based on cysto-prostatectomy specimen it appears that the biologic activity appears to be independent of serum PSA.

Ward et al, 2004

psa 2 12 ng ml not predictive for pca stamey
PSA 2-12 ng/ml not predictive for Pca (Stamey)

Schröder: PPV of PSA 3,0 ng/ml is 20% and

correlation remains significant.

Catalona: Correlation PSA & % Ca (.37-47)

Cancer Volume (.43-48)

Prostate Volume (.01-17)

AAGUS, 2005

psa pitfalls in clinical practice
PSA pitfalls in clinical practice.

Serial measurements vs. tissue (BPH) specificity.

After surgery o and other treatment’s nadir is a rise therapy failure (Biochemical relapse).

Nadir with hormonal treatment predictive for response duration.

HRPC a 50% reduction and slope show response (other markers needed).

OCA, 2005

future markers for cap tricoli et al clin cancer res 2004 10 3943
? Future Markers for CaPTricoli et al, Clin Cancer Res 2004;10:3943
  • 91 molecular markers under investigation
    • Chromogranin A
    • GSTP
    • Prostate Stem Cell Antigen
    • Prostate-specific Membrane Antigen
    • DD3PCA3
    • SELDI-TOF MS
  • Proteomics
slide21

M

M

DD3...DD3PCA3…PCA3

  • PCA3DD3 is a novel prostate-cancer-specific gene:
  • (Bussemakers et al., Cancer Res. 59: 5975-79, 1999)
  • Overexpressed in >95% of PrCa

1

2

3

4

5

6

T

B

N

T

N

T

N

T

N

(kb)

4.0

DD3

2.0

0.6

slide22

Results

  • 108 urine samples collected of 108 men with PSA > 3 ng/ml.
  • 24 men had PCa was biopsy proven
  • 84 men were negative for prostate cancer
slide23

Results

  • 14/84 men without PCa had ratios above the cut off: i.e. specificity of 80% (vs PSA 20 %)
  • 16/24 men with PCa had ratios above the cut off;
  • i.e..sensitivity of 67%
  • Negative predictive value: 88%!
psa a test for asymptomatic men
PSA: a test for asymptomatic men?

Discovered as a concept in 1970 and developed into the PSA test has never been specific enough to be a definitive test for Pca.

The PSA related concepts are flawed and lead to unnecessary treatments.

A more specific test is needed and PSA is more a smoke than a fire alarm.

Richard J. Ablin, 2001